Molecular Glue Drug Development Summit on January 24-26, 2023 in Boston, United States

Built with biopharmaceutical industry insights, this in-person meeting will bring together KOLs to delve deep into the key remaining challenges when it comes to identifying, designing and developing the next generation of molecular glues and truly unlock the widespread therapeutic potential of this promising therapy.

This forum will deliver exclusive data from the movers and shakers in the molecular glue space, from the likes of C4 Therapeutics, Monte Rosa Therapeutics, Amgen, Proxygen, Pin Therapeutics, Degron Therapeutics, Plexium and more.

As we continue enriching the design and development of molecular glues, network with 80+ leading Chemists, Biologists, Bioinformaticians, Structural Scientists and Computational Chemists at the world's first-of-a-kind meeting to successfully accelerate the first wave of molecular glues into the clinic.

URLs:

Tickets: https://go.evvnt.com/1345052-1?pid=10008 

Brochure: https://go.evvnt.com/1345052-2?pid=10008

Time: 8:00 am - 5:00 pm

Prices:

Drug Developer Pricing - Conference + 2 Workshops: USD 4297.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,

Drug Developer Pricing - Conference Only: USD 2999.00,

Academic Pricing - Conference + 2 Workshops: USD 3697.00,

Academic Pricing - Conference + 1 Workshop: USD 3148.00,

Academic Pricing - Conference Only: USD 2599.00,

Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00,

Solution Provider Pricing - Conference + 1 Workshop: USD 4348.00,

Solution Provider Pricing - Conference Only: USD 3599.00

Speakers: Aundrietta Duncan, Director, Non-Clinical Development, Salarius Pharmaceuticals, Charu Chaudhry, Senior Principal Scientist, Johnson and Johnson Services, Inc, Cheng Zhang, Scientist, Amgen, Christopher Nasveschuk, SVP, Chemical Sciences, C4 Therapeutics, Daniel Nomura, Professor, University of California at Berkeley, Daniela Santiesteban, Director - Targeted Protein and Degradation Development, Salarius Pharmaceuticals, Ekaterina Vinogradova Assistant, Professor, The Rockefeller University, Felix Hausch, Professor - Structure-Based Drug Research, Technical University Darmstadt, Fiona Pachl, Senior Scientist, AstraZeneca, Gabriel Lander, Professor, The Scripps Research Institute, Gang Lu, President and Chief Executive Officer, GluBio Therapeutics, Hyunsun Jo, Founder and Chief Executive Officer, Pin Therapeutics, Leah Fung, Chief Scientific Officer, BioTheryx, Matthias Brand, Chief Scientific Officer and Co-Founder, Proxygen GmbH, Mikko Taipale, Associate Professor - Molecular Genetics, University of Toronto, Peggy Thompson, VP Biology, Plexium Inc., Pete Wildes, VP - Cancer Biology, Revolution Medicines, Roy Pollock, Senior Vice President, Biological Sciences, C4 Therapeutics, Ryan Potts, Executive Director, Chair and Head of Induced Proximity Platform, Amgen Inc., Sharon Townson, Chief Technology Officer, Monte Rosa Therapeutics, Ted Suh, Vice President, Chemistry, Orionis Biosciences LLC, Yong Cang, Chief Scientific Officer and Co-founder, Degron Therapeutics, Yufei Xu, Senior Director - Biology, Triana Biomedicines, Zoran Rankovic, Director - Cognitive Behavioral Therapist and Chemistry Centers, St. Jude Children's Research Hospital